First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

BACKGROUND: Type 1 diabetes (T1D) is a CD4(+) T cell-driven autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells by CD8(+) T cells. Achieving glycemic targets in T1D remains challenging in clinical practice; new treatments aim to halt autoimmunity and prolong β...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Rampelbergh, Jean, Achenbach, Peter, Leslie, Richard David, Ali, Mohammad Alhadj, Dayan, Colin, Keymeulen, Bart, Owen, Katharine R., Kindermans, Martin, Parmentier, Frédéric, Carlier, Vincent, Ahangarani, Roxana R., Gebruers, Evelien, Bovy, Nicolas, Vanderelst, Luc, Van Mechelen, Marcelle, Vandepapelière, Pierre, Boitard, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210318/
https://www.ncbi.nlm.nih.gov/pubmed/37226224
http://dx.doi.org/10.1186/s12916-023-02900-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210318/
https://www.ncbi.nlm.nih.gov/pubmed/37226224
http://dx.doi.org/10.1186/s12916-023-02900-z

Ejemplares similares